The global prevalence of heart failure (HF) is around 56.19 million cases. In 2019, there were nearly 5.05 million ‘years lived with disability’ (YLDs) globally. 1 With the increasing prevalence of HF, there is a simultaneous global increase in related hospitalizations. 2 The mainstay therapy for HF has been diuretics, including furosemide, metolazone, and spironolactone, particularly for acute decompensated HF. 3,4 More recently, several studies have confirmed the utility of aquaretic agents in managing the condition.
5 What are aquaretic agents? Aquaretic agents belong to a family of vasopressin receptor antagonists, V2, in particular. Aquaretic drugs can regulate tubular water reabsorption. They induce an increase in urinary volume and urinary free water associated with a decreased urinary osmolarity and cause a consequent increase in plasma sodium. Consequently, they have shown…
